Clinical Trial Update: NMDA-enhancing Agent for Treatment of Mild Cognitive Impairment and Mild Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 study of an NMDA-enhancing agent for Alzheimer's disease and mild cognitive impairment has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• NMDA-enhancing agent

Snippet

Sponsor: Chang Gung Memorial Hospital | Conditions: Alzheimer's Disease, Mild Cognitive Impairment | Phase 2 | Status: COMPLETED